DX Technology enables direct atrial sensing for AFib detection and monitoring. Since its introduction in 2009, clinicians in more than 80 countries around the world have used DX ICDs.
The technology offers reliable, timely information about atrial arrhythmias and detects AFib early. After detection, DX ICD helps monitor AFib burden over time so clinicians can intervene when needed. They can also react to changes in patient status and optimize treatment.
In combination with Biotronik Home Monitoring, the solution offers a comprehensive assessment of ICD patients. The company says it enables earlier, well-informed decision-making.
Dr. Andreas Hecker, president of CRM/EP at Biotronik, said in a news release that the milestone implant demonstrates the company’s “collective efforts and dedication to making a positive difference and helps us define a new standard in patient care.”
“We are deeply grateful for the trust we’ve received from the medical community. We develop solutions to ease physicians’ workloads and improve patient care through holistic and connected approaches. Our innovations are rooted in trustworthy customer relations, feedback and our extensive expertise in cardiac device implants and leads,” said Dr. David Hayes, chief medical officer, Biotronik. “With this impressive milestone and the extensive clinical evidence, DX Technology has proven itself, and I am confident that we will reach more milestones such as this in the years to come.”
